Treats benign prostatic hyperplasia. ANDA 79013, held by Apotex. Alfuzosin Hydrochloride.
As of Nov 22, 2026, ANDA 79013 (Alfuzosin Hydrochloride), held by Apotex, was first approved by FDA on Jul 18, 2011, with 4 approved supplements and 0 published complete response letters.
Alfuzosin hydrochloride extended-release tablets, USP are indicated for the treatment of signs and symptoms of benign prostatic hyperplasia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 18, 2011 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Alfuzosin Hydrochloride10MG · tablet, extended release;oral | Alfuzosin Hydrochloride | Rx |
| Sep 23, 2022 | Supplement 7Labeling · Standard review | Approved | None posted |
| Dec 7, 2018 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jan 15, 2015 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jan 15, 2015 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jul 18, 2011 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters